ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GLPG Galapagos

416.00
0.00 (0.00%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Galapagos LSE:GLPG London Ordinary Share BE0003818359 ORD SHS NO NOMINAL VALUE
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 416.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Galapagos Share Discussion Threads

Chat Pages: 1
DateSubjectAuthorDiscuss
22/4/2013
15:57
Press Releases 2013

April 22, 2013
Galapagos discovers novel candidate drug to treat breast cancer
View English version - Bekijk Nederlandse versie

jammytass
04/3/2011
06:46
glpg > has made large profits and will be one of the worlds leading cmpy traded on euronext, wish they would come back to uk market!!!!
jammytass
12/10/2010
06:57
cancer contract> this cmy will be massive
jammytass
04/10/2010
07:39
more good news for this growing group> oh why oh why did they pull from lse
jammytass
20/9/2006
09:56
Mechelen, Belgium; 19 September 2006 - Galapagos NV (Euronext & LSE:
GLPG) has placed 1,305,074 new shares in a successful private
placement with Fortis Bank NV, at a price of Eur8.50 per share. Fortis
intends to place these new shares with international institutional
clients via an accelerated bookbuilding procedure. Galapagos raised
gross proceeds of Eur11.1 million.
The Board of Directors of Galapagos has authorized this capital
increase of ยค11.1 million by the issuance of 1,305,074 new ordinary
shares, effective as of 19 September 2006, at a price per share of
Eur8.50, reflecting the average share price on Euronext Amsterdam over
the last 30 days. The new shares are expected to be admitted to
trading and listing on Eurolist by Euronext Brussels and Euronext
Amsterdam and on AiM on 22 September 2006. As a result of the
placement, Galapagos will have 14,355,817 ordinary shares
outstanding.

jonwig
06/9/2006
07:50
Collaboration of BioFocus with a US research unit, revenue of $3m over 2.5 years for GLPG.
jonwig
19/7/2006
07:32
Hi gardenboy.

I held some of these for about 1 hour last year, when I took part in their T/O of Biofocus; I always meant to look more closely but never got round to it.

Since they (ie. the BioFocus division) are involved in partnering other companies' drug discovery efforts, it may be that the partner takes most of the risk, whilst they take the fees - dunno, like you I haven't done the research.

Will come back if I find anything to excite me!

A chart since admission to AIM:

jonwig
03/4/2006
17:33
no thread so here's one - invested in a few at 670p - as yet I have done no research ! but simply bought some because the share made a new high and now continues to climb - could be interesting
gardenboy
03/4/2006
17:31
Post removed by ADVFN
Abuse team
03/4/2006
17:28
Company website :
gardenboy
Chat Pages: 1

Your Recent History

Delayed Upgrade Clock